Quantcast
The Motley Fool fool.com 04 Aug, 2022 19:15 am

Why Aurinia Pharmaceuticals Stock Briefly Spiked Today

Why Aurinia Pharmaceuticals Stock Briefly Spiked Today
Investors embraced the biotech's second-quarter results.

The company also said that it is maintaining its 2022 full-year revenue guidance of between $115 million and $135 million.However, Aurinia's shares have given back most of these gains as the session has progressed.So what Why did investors bid up Aurinia's shares?Now what The long and short of it is that Aurinia's Q2 results were broadly in line with expectations.

Ahead of the opening bell, the company announced its second-quarter 2022 financial results.The biotech said that sales of its lupus nephritis medication, Lupkynis, came in at $28.

Read full story at fool.com